Friedreich's Ataxia

Last updated by Peer reviewed by Prof Cathy Jackson
Last updated Meets Patient’s editorial guidelines

Added to Saved items
This page has been archived. It has not been updated since 16/06/2014. External links and references may no longer work.
This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.

Read COVID-19 guidance from NICE

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Synonym: Friedreich ataxia

Friedreich's ataxia is the most common inherited ataxia in the UK. It is a degenerative disease that primarily affects the nervous system and the heart. It is frequently associated with cardiomyopathy or diabetes.[1]

There is progressive ataxia, dysarthria, decreased proprioception/vibration sense and muscle weakness. The inheritance is autosomal recessive.

Friedreich's ataxia was first described in 1863 by Nikolaus Friedreich, a German physician. The Friedreich's ataxia gene was discovered in 1996, leading to better recognition of the spectrum of disease.

  • The prevalence is about 1.8 per 100,000 in the UK.
  • Friedreich's ataxia occurs in populations from Europe, the Middle East, North Africa and India. It is absent in populations from East Asia (China and Japan) and in American Indians.
  • The gene disorder is a mutation of the frataxin gene on chromosome 9.
  • Most patients (98%) have a GAA repeat expansion of the frataxin gene; the size of the expansion correlates with the severity of the disease.[5]
  • More rarely there is a point mutation in one gene.
  • The mutation results in decreased synthesis of frataxin, a mitochondrial protein.
  • The function of frataxin protein is unknown, but it seems to be involved in cellular iron homeostasis. Its dysfunction results in mitochondrial dysfunction and oxidative damage to cells.[6]
  • The cellular damage primarily affects the nervous system and the heart (for unknown reasons). The sensory neurones involving proprioception are affected early and severely - so ataxia is an early feature of the disease.[6]

Friedreich's ataxia is a progressive neurodegenerative disorder, typically with onset before 20 years of age. Signs and symptoms include progressive ataxia, ascending weakness and ascending loss of vibration and joint position senses, pes cavus, scoliosis, cardiomyopathy, and cardiac arrhythmias.[7]


  • Usually presents before adolescence, with onset between ages 2-16 years.
  • Late-onset presentation is possible, up to age 50 years with milder forms of Friedreich's ataxia.

Presenting symptoms

  • Unsteadiness of gait is the usual presenting symptom.
  • Other presenting symptoms are general clumsiness or deterioration in athletic performance.
  • Sometimes presents with scoliosis or pes cavus, which may precede neurological symptoms by several years.
  • May present (rarely) with symptoms of cardiomyopathy.
  • In one case report, presentation was without ataxia but with visual, motor and sensory loss.[8]

Neurological features

  • Ataxia mostly results from degeneration of the dorsal root ganglia neurons, resulting in afferent ataxia.
  • Involvement of the cranial nerves may cause dysarthria, vision and hearing loss and dysphagia.
  • Neurological signs are:
    • Progressive ataxia of the limbs and gait.
    • Extensor plantar responses.
    • Dysarthria (may begin >5 years after onset).
    • Areflexia.
    • Pyramidal weakness in the lower limbs.
    • Loss of joint position and vibration sense in the lower limbs.
    • Hearing loss and visual disturbance (optic atrophy or nystagmus) are common.

Other clinical features or complications[2, 3]

  • Orthopaedic - scoliosis and symmetrical pes cavus develop in most patients.
  • Hypertrophic cardiomyopathy - left ventricular hypertrophy develops in about 75% of patients and conduction disturbances in 10%.[2] However, cardiac symptoms are relatively rare and occur late in the disease.[4]
  • Optic atrophy occurs in 25-50% of patients.
  • Diabetes mellitus develops in about 10% of patients.[9]
  • Hearing loss (usually in the later stages of disease).
  • Peripheral cyanosis, oedema and cold feet can be a problem, due to reduced muscle activity.[4]
  • Vitamin E deficiency can produce an identical picture - important to diagnose as it is treatable.[4]
  • The differential diagnosis is wide because many diseases can cause early-onset, progressive ataxia with a chronic course.
  • Clinical history and investigations should look for toxic, metabolic and immune diseases, paraneoplastic disorders, malformations, posterior fossa tumours, multiple sclerosis and leukodystrophies.
  • Friedreich's ataxia cannot be confidently excluded on clinical grounds. However, Friedreich's ataxia is very unlikely in the presence of early prominent cerebellar atrophy, general learning disability, and preserved sensory nerve action potentials.
  • Consider other causes of scoliosis or cardiomyopathy (if these are presenting symptoms).

A diagnostic algorithm for chronic, progressive ataxias in childhood is available.[2]

Initial investigations

  • Nerve conduction studies show motor velocities >40 ms-1 in arms and absent sensory action potentials.
  • Genetic analysis.
  • ECG - there may be ventricular hypertrophy and T-wave inversion.
  • Exclude vitamin E deficiency.

Further investigations[2]

  • Blood tests: FBC, U&E and glucose
  • Echocardiography - may show ventricular hypertrophy, septal hypertrophy and hypertrophic cardiomyopathy.
  • MRI scan of the brain and spinal cord - shows characteristic atrophic changes, particularly of the cervical spinal cord.
  • Brainstem auditory evoked responses and visual evoked potentials - may be abnormal.
  • Genetic counselling and tests - prenatal diagnosis is available. Carrier testing for relatives of affected patients and their partners is also possible.

A multidisciplinary approach is needed. This should include a neurologist, a geneticist, a genetic counsellor, physiotherapists, speech and language therapists, occupational therapists and social workers. Other specialities may be involved for specific problems - eg, cardiology, orthopaedics and diabetes specialists.

Friedreich's ataxia is a disease with multisystem involvement. Annual reviews should include assessment of neurology, cardiac function, musculoskeletal problems, a comprehensive systems review and blood tests (haematology and monitoring for diabetes).

There has been increased interest in developing new treatments such as cell and/or gene therapies.[10]

Specific drug treatment

Most trials so far have focused on antioxidant therapy.

  • No random controlled trial using idebenone or any other pharmacological treatment has shown significant benefit on neurological symptoms associated with Friedreich's ataxia.[11, 12]
  • Other possible treatments include deferiprone (an iron chelator), erythropoietin, pioglitazone and histone deacetylase (HDAC) inhibitors and peroxisome proliferator-activated receptor (PPAR)-gamma agonists.[13, 14]

Supportive treatment[2, 4]

May include:

  • Physiotherapy.
  • Speech and language therapy.
  • Occupational therapy.
  • Liaison with educational and social services.
  • Treatment of cardiac failure and/or arrhythmias - using standard treatments.
  • Orthopaedic surgery if there are troublesome symptoms from scoliosis, pes cavus or equinovarus deformity of feet.
  • Foot deformities may also be helped by botulinum toxin or splints.
  • Passive exercises and warming for peripheral cyanosis and cold feet.
  • Diabetes (if present) will usually require insulin.
  • Sphincter dysfunction symptoms (eg, urgency) should be monitored. Urodynamic assessment and treatments such as oxybutinin may be helpful.
  • Sexual dysfunction may require symptomatic treatment.
  • Counselling or antidepressants for depression (selective serotonin reuptake inhibitors (SSRIs) are probably the most suitable antidepressant).
  • Dysphagia may require dietary modification or (in later stages of disease) gastrostomy.
  • Anaesthesia - propofol should probably be avoided.
  • Pregnancy - potential complications are cardiac and respiratory impairment, pulmonary embolism and preterm labour. Unusual sensitivity to magnesium sulfate (for pre-eclampsia) has been reported.
  • Average life expectancy is 40-50 years, but disease severity and progression vary; some patients live into their seventies.
  • Loss of ability to walk typically occurs about 15 years after diagnosis.
  • The most commonly reported causes of death are cardiac failure and arrhythmias.

Further reading and references

  1. Puccio H, Anheim M, Tranchant C; Pathophysiogical and therapeutic progress in Friedreich ataxia. Rev Neurol (Paris). 2014 May170(5):355-65. doi: 10.1016/j.neurol.2014.03.008. Epub 2014 Apr 29.

  2. Schulz JB, Boesch S, Burk K, et al; Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol. 2009 Apr5(4):222-34.

  3. Brice A; Friedreich ataxia, Orphanet, 2004

  4. Friedreich's ataxia: a guide for the medical profession; Ataxia UK

  5. Delatycki MB, Corben LA; Clinical features of Friedreich ataxia. J Child Neurol. 2012 Sep27(9):1133-7. doi: 10.1177/0883073812448230. Epub 2012 Jun 29.

  6. Pandolfo M; Friedreich ataxia. Arch Neurol. 2008 Oct65(10):1296-303.

  7. Collins A; Clinical neurogenetics: friedreich ataxia. Neurol Clin. 2013 Nov31(4):1095-120. doi: 10.1016/j.ncl.2013.05.002.

  8. Diehl B, Lee MS, Reid JR, et al; Atypical, perhaps under-recognized? An unusual phenotype of Friedreich ataxia. Neurogenetics. 2010 Feb 17.

  9. Pandolfo M; Friedreich ataxia: the clinical picture. J Neurol. 2009 Mar256 Suppl 1:3-8. doi: 10.1007/s00415-009-1002-3.

  10. Evans-Galea MV, Pebay A, Dottori M, et al; Cell and gene therapy for Friedreich ataxia - progress to date. Hum Gene Ther. 2014 Apr 21.

  11. van de Warrenburg BP, van Gaalen J, Boesch S, et al; EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood. Eur J Neurol. 2014 Apr21(4):552-62. doi: 10.1111/ene.12341. Epub 2014 Jan 13.

  12. Kearney M, Orrell RW, Fahey M, et al; Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst Rev. 2012 Apr 184:CD007791. doi: 10.1002/14651858.CD007791.pub3.

  13. Tsou AY, Friedman LS, Wilson RB, et al; Pharmacotherapy for Friedreich ataxia. CNS Drugs. 200923(3):213-23. doi: 10.2165/00023210-200923030-00003.

  14. Marmolino D, Acquaviva F; Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising Cerebellum. 2009 Sep8(3):245-59. Epub 2009 Jan 23.